Table 2 Demographic and medical characteristics of the participating colorectal cancer survivors (n = 96)
Time since surgery, mean (SD), months | 78·3 (5·5) |
|---|---|
Age at follow-up, mean (SD), years | 69·9 (10·3) |
No. (%) of participants | |
Former intervention group patient (%) | 45 (47) |
Male (%) | 65 (68) |
Marital status at diagnosis | |
Married | 80 (83) |
Unmarried | 7 (7) |
Widowed | 5 (5) |
Divorced | 4 (4) |
Children at diagnosis | |
Yes | 79 (82) |
No | 13 (14) |
Unknown | 4 (4) |
Daily living (%) | |
Urban area | 33 (34) |
Rural area | 63 (66) |
Prognostic stage at diagnosis | |
UICC I | 32 (33) |
UICC II | 17 (18) |
UICC III | 40 (42) |
UICC IV | 7 (7) |
Primary site of disease | |
Colon | 51 (53) |
Rectum | 45 (47) |
Surgical access | |
Open | 58 (60) |
Laparoscopic | 38 (40) |
ASA at diagnosisb | |
ASA I | 17 (18) |
ASA II | 48 (50) |
ASA III | 29 (30) |
ASA IV | - |
Unknown | 2 (2) |
Comorbidities at diagnosis | |
Cardiovascular | 25 (26) |
Kidney | 8 (8) |
Lung | 12 (13) |
Central nervous system | 8 (8) |
Stoma (%) | 37 (39) |
Reversed stoma | 26 (70) |
Preoperative symptoms | |
Abdominal pain | 26 (27) |
Anaemia | 18 (18) |
Ileus | 1 (1) |
Bleeding | 44 (46) |
Neoadjuvant therapy | |
Chemotherapy + radiotherapy | 27 (28) |
No neoadjuvant therapy | 69 (72) |
Adjuvant therapy (18 months after surgery) | |
Chemotherapy | 43 (45) |
Antibody therapy | 1 (1) |
No adjuvant therapy | 52 (54) |